Impact of Diabetes Duration on Efficacy and Safety of a Basal-Plus Regimen of Insulin Glargine Plus Once Daily Insulin Glulisine: A Pooled Analysis From 4 Clinical Trials

被引：0
|
作者：
Owens, David R.
Del Prato, Stefano
Lin, Jay
Wang, Edward
Lankisch, Mark
机构：
来源：
DIABETES | 2012年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2378-PO
引用
收藏
页码：A599 / A599
页数：1
相关论文
共 50 条
  • [21] Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape)
    Vora, J.
    Cohen, N.
    Evans, M.
    Hockey, A.
    Speight, J.
    Whately-Smith, C.
    [J]. DIABETES OBESITY & METABOLISM, 2015, 17 (12): : 1133 - 1141
  • [22] Comparison of a Multiple Daily Insulin Injection Regimen (Basal Once-Daily Glargine Plus Mealtime Lispro) and Continuous Subcutaneous Insulin Infusion (Lispro) in Type 1 Diabetes A randomized open parallel multicenter study
    Bolli, Geremia B.
    Kerr, David
    Thomas, Reena
    Torlone, Elisabetta
    Sola-Gazagnes, Agnes
    Vitacolonna, Ester
    Selam, Jean Louis
    Home, Philip D.
    [J]. DIABETES CARE, 2009, 32 (07) : 1170 - 1176
  • [23] Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal–Bolus Insulin: Phase 4 OPTIMIZE Study
    Chantal Mathieu
    S. John Weisnagel
    Peter Stella
    Jacques Bruhwyler
    Kathy Alexandre
    [J]. Diabetes Therapy, 2020, 11 : 495 - 507
  • [24] Comparison of Prandial AIR Inhaled Insulin Alone to Intensified Insulin Glargine Alone and to AIR Insulin Plus Intensified Insulin Glargine in Patients with Type 2 Diabetes Previously Treated with Once-Daily Insulin Glargine
    Rosenstock, Julio
    Eliaschewitz, Freddy G.
    Heilmann, Cory R.
    Muchmore, Douglas B.
    Hayes, Risa P.
    Belin, Ruth M.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2009, 11 : S63 - S73
  • [25] Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial
    Rosenstock, Julio
    Lorber, Daniel L.
    Gnudi, Luigi
    Howard, Campbell P.
    Bilheimer, David W.
    Chang, P-C
    Petrucci, Richard E.
    Boss, Anders H.
    Richardson, Peter C.
    [J]. LANCET, 2010, 375 (9733): : 2244 - 2253
  • [26] Comparison of the efficacy and safety of insulin degludec/aspart (twice-daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal-bolus therapy)
    Kawaguchi, Yuji
    Sawa, Jun
    Hamai, Chie
    Nishimura, Yuri
    Kumeda, Yasuro
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2019, 10 (06) : 1527 - 1536
  • [27] Efficacy and safety of insulin glulisine versus insulin lispro as part of a basal-bolus insulin regimen in children and adolescents with type I diabetes mellitus
    Philotheou, A.
    Arslanian, S.
    Blatniczky, L.
    Peterkova, V.
    Souhami, E.
    Danne, T.
    [J]. DIABETOLOGIA, 2008, 51 : S382 - S382
  • [28] Efficacy and safety of post-meal insulin glulisine (GLU) compared with pre-meal regular human insulin (RHI) in a basal-bolus regimen with insulin glargine
    Garg, S
    Rosenstock, J
    Ways, K
    [J]. DIABETES, 2004, 53 : A125 - A125
  • [29] Efficacy and Safety in Patients Switched to an Insulin Glargine Plus Rapid-Acting Analog Basal-Bolus Regimen: The GLAD Study
    Oroszlan, Tamas
    [J]. DIABETES, 2011, 60 : A604 - A605
  • [30] Safety and Efficacy of Insulin Glargine Compared with NPH Insulin in Older Adults with Type 2 Diabetes: Results from a Pooled Analysis
    Lee, Pearl G.
    Chang, Annette M.
    Blaum, Caroline S.
    Vlajnic, Aleksandra A.
    Miller, Michael F.
    Halter, Jeffrey B.
    [J]. DIABETES, 2009, 58 : A155 - A155
12345